NuVue Therapeutics, Inc. is a medical device, diagnostics, and drug delivery company with an initial focus on accurate diagnosis and targeted treatment of liver, pancreatic, and other hard-to-treat soft-tissue cancers. In 1971, NuVueâs Founder and Chief Executive Officer, Roger Kolasinski, founded Kol Bio-Medical Instruments, Inc., a highly successful medical device and therapeutic Specialty Distribution Company that went on to achieve peak sales of some $45 million per year. Mr. Kolasinski based Kolâs success on focusing on innovative but sound disruptive technologies that fulfilled existing unmet clinical needs. Motivated by the loss of his mother and brother to cancer, Mr. Kolasinski determined to fill unmet clinical needs in oncology, and in particular, avoiding the toxic effects of systemic chemotherapy. In pursuit of these goals, in 1999 Mr. Kolasinski set about strategically acquiring innovative technologies that would create a completely new way of treating soft tissue cancers, especially hard-to-treat cancers such as unresectable liver and pancreatic cancer
